Fig 1: SLC7A8 mRNA expression and its association with copy number aberrations, clinicopathological parameters and molecular subtypes: a SLC7A8 and copy number aberrations, bSLC7A8 and tumour size, cSLC7A8 and tumour grade, dSLC7A8 and lymph node stage, eSLC7A8 and NPI, fSLC7A8 and PAM50 subtypes, gSLC7A8 and METABRIC Integrative Clusters. Pearson correlation was used for two variables and One-way ANOVA with post hoc tukey test for more than two variables
Fig 2: SLC7A8 protein and breast cancer patient outcome. a SLC7A8 vs BCSS in all cases, b SLC7A8 vs BCSS of ER+—low proliferation tumours, c SLC7A8 vs BCSS of ER+—high Proliferation tumours, d SLC7A8 vs BCSS of HER2+ tumours, e SLC7A8 vs BCSS of Triple Negative tumours
Fig 3: SLC7A8 mRNA and breast cancer patient outcome. aSLC7A8 vs BCSS in all cases, bSLC7A8 vs BCSS in luminal A tumours, cSLC7A8 vs BCSS in Luminal B tumours, dSLC7A8 vs BCSS in HER2+ tumours, eSLC7A8 vs BCSS in Triple Negative tumours
Supplier Page from MilliporeSigma for Anti-SLC7A8 antibody produced in rabbit